Want to see HK:1652 full AI Analyst Report?
Top Page
Fusen Pharmaceutical Co., Ltd.
(1652)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.78
▼(-3.00% Downside)
Action:Reiterated
Date:08/26/26
The score is held back mainly by sustained losses and weakened margins (despite improving revenue) and a bearish technical backdrop with price below key moving averages and negative MACD. Positive operating/free cash flow supports the financial profile, but negative earnings and lack of dividend support keep valuation and overall risk/reward muted.
Positive Factors
Recent Cash Generation
Positive operating and free cash flow provide internal funding for operations and reduce reliance on external capital. Although recent cash generation is volatile, its presence offers useful support while management works to restore profitability.
Negative Factors
Sustained Unprofitability
Multi-year losses show that revenue recovery has not yet translated into dependable earnings. Continued unprofitability can erode financial flexibility, limit reinvestment capacity, and make the business more dependent on cash reserves or additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent Cash Generation
Positive operating and free cash flow provide internal funding for operations and reduce reliance on external capital. Although recent cash generation is volatile, its presence offers useful support while management works to restore profitability.
Read all positive factors
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$566.12M
Dividend Yield1.15%
Average Volume (3M)108.07K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth18.14%
EPS Growth98.32%
CountryHK
Employees1,005
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding739,301,000
10 Day Avg. Volume148,900
30 Day Avg. Volume108,066
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)1.94
P/FCF Ratio7.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product p...
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
54
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 273.37M | 326.03M | 565.61M | 491.76M | 385.66M |
| Gross Profit | 109.79M | 162.64M | 299.51M | 225.02M | 211.13M |
| EBITDA | 11.55M | -39.07M | 18.93M | 49.90M | 55.82M |
| Net Income | -11.78M | -188.78M | -36.28M | -34.65M | 16.64M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.24B | 1.34B | 1.35B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 83.88M | 21.06M | 34.85M | 128.11M | 81.70M |
| Total Debt | 324.34M | 383.69M | 344.12M | 228.38M | 240.69M |
| Total Liabilities | 891.02M | 869.80M | 781.52M | 737.38M | 582.39M |
| Stockholders Equity | 359.40M | 369.67M | 563.52M | 614.17M | 658.17M |
Cash Flow | |||||
| Free Cash Flow | 69.98M | 57.43M | -161.84M | 86.63M | -62.37M |
| Operating Cash Flow | 121.93M | 133.73M | -73.33M | 110.49M | 47.77M |
| Investing Cash Flow | -5.88M | -163.42M | -108.32M | -13.13M | -282.98M |
| Financing Cash Flow | -56.21M | 15.99M | 88.50M | -51.77M | 20.53M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Negative
0.80
Price Trends
0.99
Negative
1.05
Negative
0.98
Negative
Market Momentum
-0.08
Positive
28.76
Positive
44.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1652, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 0.99, and below the 200-day MA of 0.98, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 28.76 is Positive, neither overbought nor oversold. The STOCH value of 44.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1652.
Fusen Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$715.43M | 4.61 | 7.52% | 3.77% | 7.05% | 22.46% | |
59 Neutral | HK$1.51B | 5.64 | 6.78% | 9.55% | 6.55% | 36.62% | |
54 Neutral | HK$229.10M | -0.20 | -154.56% | ― | -7.12% | -523.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$339.89M | 86.11 | 0.34% | 84.69% | -8.30% | -44.44% | |
44 Neutral | HK$566.12M | -205.93 | -0.66% | 1.15% | 18.14% | 98.32% | |
43 Neutral | HK$139.08M | -4.57 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.77
0.41
113.89%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.04
-34.45%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.05
-13.89%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.20
-0.87
-42.27%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.19
-42.22%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.01
-0.16
-13.44%
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical Sets Board Meeting to Review Interim Results and Dividend
Aug 19, 2026
Fusen Pharmaceutical Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026, and to consider their release to the market. The board will also delib...
Fusen Pharma Wins Spot for Four Drugs in China’s Latest Centralised Procurement Round
Aug 3, 2026
Fusen Pharmaceutical Company Limited said four of its drugs, including nicardipine injection, azilsartan medoxomil potassium tablets, compound potassium hydrogen phosphate injection and dydrogesterone tablets, have been selected in the twelfth bat...
Fusen Pharmaceutical Extends Completion Date for Henan Equity Transaction
Jul 30, 2026
Fusen Pharmaceutical Company Limited has announced an extension to the completion date of a major transaction involving a deemed disposal of equity interest in Henan Fusen Pharmaceutical Company Limited via a capital increase. All conditions prece...
Fusen Pharmaceutical Wins China Approval for New Doxazosin Extended-Release Tablets
Jul 10, 2026
Fusen Pharmaceutical Company Limited has secured marketing approval from China’s National Medical Products Administration for its Doxazosin Mesylate Extended-Release Tablets, branded Yijianping, for treating hypertension and the symptoms of ...
Fusen Pharmaceutical Shareholders Approve RMB300 Million Capital Injection into Henan Subsidiary
Jul 9, 2026
Shareholders of Fusen Pharmaceutical Company Limited have approved an ordinary resolution at an extraordinary general meeting in Hong Kong, authorising a capital increase in Henan Fusen Pharmaceutical Company Limited, the group’s key operati...
Fusen Pharmaceutical Wins China Nod for Peramivir Flu Injection
Jun 26, 2026
Fusen Pharmaceutical said its wholly owned unit Jiaheng Pharmaceutical has secured Chinese regulatory approval to market Peramivir Injection for treating influenza A and B, adding an FDA-approved anti-influenza intravenous drug to its portfolio. T...
Fusen Pharmaceutical Seeks Shareholder Approval for RMB300 Million Capital Injection
Jun 22, 2026
Fusen Pharmaceutical Company Limited has called an extraordinary general meeting in Hong Kong on 9 July 2026 to seek shareholder approval for a capital increase agreement involving its subsidiary Henan Fusen Pharmaceutical Company Limited. The pro...
Fusen Pharmaceutical to Dilute Stake in Henan Unit via RMB300 Million Capital Increase
Jun 18, 2026
Fusen Pharmaceutical Company Limited plans a major capital restructuring at its mainland subsidiary Henan Fusen Pharmaceutical, with external investors committing RMB300 million for newly issued equity. After the capital injection, the investors w...
Fusen Pharmaceutical Sets July EGM to Approve Capital Increase Plan
Jun 18, 2026
Fusen Pharmaceutical Company Limited has scheduled an extraordinary general meeting for 9 July 2026 in Hong Kong to seek shareholder approval for a Capital Increase Agreement and related transactions, a move that could affect the company’s c...
Fusen Pharma Wins China Approval for New Piracetam Injection Formats
Jun 16, 2026
Fusen Pharmaceutical Company Limited has secured marketing approval in mainland China for additional specifications of its Piracetam Injection, a cerebral metabolism-enhancing agent used to treat memory impairment, mild to moderate cerebral dysfun...
Fusen Pharmaceutical Wins China Nod to Market Agomelatine Antidepressant
Jun 8, 2026
Fusen Pharmaceutical Company Limited has secured approval from China’s National Medical Products Administration to market its Agomelatine Tablets, developed by its wholly owned unit Henan Fusen Pharmaceutical, for treating depression in adul...
Fusen Pharmaceutical Shareholders Approve All AGM Resolutions, Renew Capital Mandates
May 29, 2026
Fusen Pharmaceutical Company Limited reported that shareholders at its 29 May 2026 annual general meeting in Hong Kong approved all resolutions put forward by the board. The audited financial statements for the year ended 31 December 2025 were ado...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.